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Small, noncoding microRNAs (miRNAs) have been
shown to be abnormally expressed in every tumor
type examined. We used comparisons of global
miRNA expression profiles of head and neck squa-
mous cell carcinoma (HNSCC) samples and adjacent
normal tissue to rank those miRNAs that were most
significantly altered in our patient population. Rank
Consistency Score analysis revealed miR-375 to have
the most significantly lowered miRNA levels in tu-
mors relative to matched adjacent nonmalignant tis-
sue from the same patient among 736 miRNAs that
were evaluated. This result has been previously ob-
served by other groups; however, we extend this find-
ing with the unique observation that low miR-375
expression levels correlate significantly with cancer
survival and distant metastasis. In a study of 123 pri-
mary HNSCC patients using multivariable Cox pro-
portional hazard ratios (HR) and 95% confidence in-
tervals (CI), both death from disease (HR: 12.8, 95%
CI: 3 to 49) and incidence of distant metastasis (HR:
8.7, 95% CI: 2 to 31) correlated with lower expression
levels of miR-375 regardless of the site or stage of the
tumor. In addition, we found that oral cavity tumor
cell lines (eg, UMSCC1 and UMSCC47) overexpressing
miR-375 were significantly less invasive in vitro thantheir matched empty vector controls. We conclude
that miR-375 represents a potential prognostic
marker of poor outcome and metastasis in HNSCC
and that it may function by suppressing the tumor’s
invasive properties. (Am J Pathol 2012, 180:917–928; DOI:
10.1016/j.ajpath.2011.12.004)
Noncoding microRNAs (miRNAs) are abnormally ex-
pressed in every malignant cell type examined, including
head and neck squamous cell carcinoma (HNSCC).
These small RNAs post-transcriptionally regulate protein
abundance by destabilizing target mRNAs or translation-
ally inhibiting protein synthesis. A ubiquitous feature in
tumor cells is the aberrant expression of a disease-spe-
cific set of miRNAs that result in altered downstream
levels of groups of mRNAs and proteins targeted by the
specific miRNAs.1–8 Known miRNA targets can control
basic cellular processes such as cell proliferation, apop-
tosis, and differentiation,2–4 and as a result of this regu-
latory role in modulating critical pathways and networks
of genes, they represent potential biomarkers of disease
phenotypes. MiRNAs can function either as tumor sup-
pressors (typically deleted or repressed in tumors) or
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AJP March 2012, Vol. 180, No. 3as oncogenes (when amplified or otherwise overex-
pressed).2,7,8 Subsets of miRNAs have subsequently
been identified as potential diagnostic and prognostic
markers in a variety of cancers.9–16
Head and neck cancer is the sixth most common ma-
lignancy in men worldwide, representing a major interna-
tional health problem. It constitutes an anatomically het-
erogeneous group arising most often from the oral cavity,
larynx and oropharynx. The 5-year survival rate for HN-
SCC (ca. 50%) has remained relatively unchanged over
the past 3 to 4 decades. Efforts to identify biomarkers for
HNSCC have been numerous, and none have proven to
be useful clinically as a guide to treatment selection at
initial diagnosis. Studies on p53, EGFR, Bcl-2, MMPs,
cyclins and molecular markers have demonstrated incon-
sistent and at times contradictory results.17–19 High
throughput genomic technologies have shed new light on
alterations in gene expression that are associated with
HNSCC carcinogenesis. Initial classification studies by
our group demonstrated that there is a link between the
gene expression profiles of patient HNSCC tumor sam-
ples and the clinical outcome for that patient, suggesting
that custom profiles can be developed to predict out-
come.20 A conclusion of this study was that tumors orig-
inating from these different locations can exhibit varying
behavior that is not predictable by histopathology of the
primary tumor but is discernable by gene profiling. In one
of the early studies to link gene expression profiling to
treatment response, Hanna et al21 identified 60 tumor-
related genes from a cDNA microarray containing 1187
genes that could successfully predict the radiation re-
sponse of tumor samples. In oral cancer, Warner and
colleagues22 identified 23 differentially expressed genes
that correlated with tumor stage (III to IV) and metastasis.
Gene expression signatures have also been identified
that are associated with recurrence of HNSCC disease.23
With the results of these and other experiments, it is
becoming increasingly clear that analysis of gene ex-
pression patterns has a valuable predictive and prognos-
tic capacity. One of the most promising aspects of mo-
lecular classification is the possibility of isolating smaller
subsets of genes whose expression (or lack thereof) cor-
relates significantly with clinical parameters, and the pos-
sibility of constructing a disease-specific assay based on
such subsets that can be used to classify cancers and
predict clinical outcome. MiRNAs offer a potentially pow-
erful tool to reach this goal.
There have been several studies investigating miRNA
expression in HNSCC cell lines and primary tumors from
which a host of over- and underexpressed miRNAs have
been identified.11–13,24–29 We previously demonstrated that
low-level expression of miR-205 is significantly associated
with local or regional recurrence in HNSCC, independent of
disease stage at diagnosis and treatment, and that com-
bined low levels of miR-205 and let-7d expression were
associated with poor head and neck cancer survival.11
Other laboratories have correlated poor prognosis of oral
carcinoma with high expression of miR-211,12 locore-
gional disease recurrence and overall survival in HNSCC
with high levels of miR-210,12 and poor overall HNSCC
survival with miR-137 promoter hypermethylation.28To identify additional prognostic miRNAs for HNSCC,
we have conducted a more extensive microarray analysis
of tumors and matched normal tissue derived from three
anatomical sites and analyzed the data using a Rank
Consistency Score algorithm developed by Navon and
colleagues.30 The most highly significant miRNA in our
dataset is miR-375, which is down-regulated in a large
fraction of patient tumor samples examined across the
three anatomical HNSCC sites. In this report, we docu-
ment the association of miR-375 with HNSCC phenotypes
using multivariate analysis methods and further demon-
strate that miR-375 expression affects the invasive prop-
erties of HNSCC cell lines.
Materials and Methods
Study Population and Clinical Samples
The study cohort consisted of 123 prospectively enrolled
patients with histologically confirmed primary HNSCC un-
dergoing curative treatment at Montefiore Medical Center
from 2002 onward. Detailed demographic and clinico-
pathological data, including information on smoking his-
tory and alcohol consumption, were collected at enroll-
ment by medical interview, along with pathological
staging on the tumors. Institutional Review Boards at
Montefiore Medical Center and Albert Einstein College of
Medicine approved the study protocol, and all patients
provided written informed consent.
Tumor and adjacent normal tissue samples were col-
lected by surgical resection or biopsy and snap-frozen in
liquid nitrogen in the same pathology laboratory within
minutes of collection. Frozen tissue was screened by the
attending pathologist for the presence of tumor cells and
homogenized before DNA and RNA extraction. Histolog-
ical confirmation of tumors was based on the American
Joint Committee on Cancer classification.
Microarray Analysis of Tumor and Normal
Samples
Total RNA was extracted from tumor and normal tissue
specimens by homogenizing the tissue in 1 mL of TRIzol
(Invitrogen 15596, Invitrogen, Carlsbad, CA) solution,
and the RNA was extracted using a standard TRIzol
protocol. The quality and quantity of the isolated RNA
was assessed spectrophotometrically using a NanoDrop
ND-1000 spectrophotometer (NanoDrop, Wilmington,
DE). RNA quality was assayed on an Agilent Bioanalyzer,
and all RNA samples were stored at 80°C in ethanol;
200 ng of total RNA from each specimen was used for
miRNA microarray analysis using the Illumina DASL (cD-
NA-mediated Annealing, Selection, Extension, and Liga-
tion) assay using the 96-well-plate Sentrix Array Matrix
(SAM) format (Illumina, San Diego, CA).31 The results of
the hybridizations were assessed within Illumina’s Ge-
nomeStudio software using their labeling and hybridiza-
tion quality controls.
There are many sources of variability when analyzing
differential expression of miRNAs, including interpatient
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says and sample composition. To minimize these issues,
we compared matched primary tumor and normal tissue
on an initial sample of 41 HNSCC cases, with represen-
tation across all three anatomical sites that were prese-
lected because they had at least 70% or greater tumor
component in the tumor specimens as determined by
histological analysis, using a Rank Consistency Score
(RCoS) method.30 RCoS utilizes discrete order statistics
on the distribution of paired samples to ascertain statis-
tical significance of differential expression. Using the Il-
lumina miRNA analysis system,31 miRNA expression lev-
els were measured, and a ratio of primary tumor to normal
tissue was generated for each miRNA. The continuous
ratio values were transformed into a discrete variable and
ranked by RCoS. Of 736 miRNAs measured on the Illu-
mina microarray platform, RCoS analysis identified 56
significantly down-regulated and 60 significantly up-reg-
ulated miRNAs in tumors compared to their respective
paired normal tissue (Table 1). Table 1 contains the sig-
nificance and tissue specificity of these 116 miRNAs
across three anatomical sites of HNSCC. Here, we also
report that hsa-miR-375 was the single most significantly
down-regulated miRNA in each of the three anatomical
tumor sites studied.
Follow-Up and Clinical Analyses
We conducted further statistical analyses to assess the
association between miR-375 expression and clinical
outcome in a larger population sample of 123 primary
HNSCC patients at Montefiore Medical Center. Median
differences in miR-375 expression in tumors compared to
adjacent normal tissues from the same patient were
tested for by nonparametric signed rank test for paired
data. Differences in proportions of low versus high miR-
375 tumor to adjacent normal tissue expression were
assessed by demographic and clinicopathological char-
acteristics at diagnosis using contingency tables and 2
tests. Patients were followed prospectively from time of
diagnosis. Detailed treatment information (primary sur-
gery, radiation, and chemotherapy), and evidence of dis-
ease following completion of primary therapy, ascer-
tained by imaging and pathological evaluation, was
collected for all patients. Disease-specific survival was
defined as time from diagnosis (in months) to death due
to head and neck cancer. Progression-free survival was
assessed by evaluating the time to incident local or re-
gional recurrence, and distant metastasis.
To evaluate survival and disease progression in pa-
tients by miR-375 tumor-to-normal (T:N) expression, we
plotted Kaplan-Meier curves to show survival functions
by miR-375 expression status, and constructed multivari-
able Cox proportional hazards regression models to es-
timate the relative hazard ratios (HR) and 95% confi-
dence intervals (CI) of dying and developing a
locoregional recurrence or distant metastasis, adjusting
for other prognostic indicators and confounders. The po-
tential for confounding was examined for all demographic
and clinicopathological characteristics at diagnosis: age,
sex, race, ethnicity, smoking history, alcohol consump-tion, human papillomavirus (HPV) detection in the tumor
(tested using a previously described protocol),32 tumor
anatomic site, TNM staging (for tumor, node, metastasis),
Eastern Cooperative Oncology Group performance sta-
tus, as well as primary treatment regimen. Confounding
factors were identified using a change in point estimate
criterion in the multivariable regression models.33
Validation of Microarray Data
The Illumina microarray platform has been extensively
validated by both quantitative real-time PCR and se-
quencing-based technologies.31,34,35 In this study, three
96-well SAMs were used. Included on each SAM was an
identical 200-ng primary HNSCC tumor total RNA sample
(HN250) used as a technical replicate. Analysis of these
technical replicates on the three SAMs for batch effects
and for variability in the assay using scatter plots showed
a minimum Spearman rank correlation of 0.94 (see Sup-
plemental Figure S1 at http://ajp.amjpathol.org). In addi-
tion, a squamous cell carcinoma (SCC) T:N pair from oral
cavity was duplicated on a second SAM containing
mostly oropharyngeal SCC samples as a technical repli-
cate and likewise an oropharyngeal and larynx SCC T:N
pair were replicated on each SAM. Results of these ad-
ditional technical replicates from different anatomical
sites also showed a Spearman rank correlation of 0.94 or
better (data not shown).
We further validated our microarray results using in situ
hybridization to pairs of samples with low and high miR-
375 expression levels (see Supplemental Figure S2 at
http://ajp.amjpathol.org). These experiments were per-
formed using the 1-day in situ hybridization procedure
from Jørgensen and colleagues36 with our modifications
of the protocol described by Giricz et al37 Pancreatic
tissue was used as a control for miR-375 expression in
the islets of Langerhans (as published by Giricz et
al).37,38 For all experiments, miR-375 (40 nmol/L), the
small nucleolar RNA U6 (10 nmol/L) used as a positive
control, and the scramble probe (40 nmol/L) used as a
negative control were analyzed simultaneously on three
adjacent head-and-neck tissue sections (5 m). The ab-
solute levels of miR-375 in these tumor tissues are con-
siderably lower than many of the abundant miRNAs in the
cells, such as miR-21, miR-205, and the let-7 family. Most
of the detectable in situ hybridization signal for miR-375 is
nuclear. We cannot explain this observation except to hy-
pothesize that at more abundant levels, cytoplasmic detec-
tion would be observed as we observed in pancreatic tis-
sue.37 Still, the observed expression of miR-375 in the
HNSCC tumors reflects the microarray data and serves to
validate that hybridization platform for miR-375 detection.
To additionally validate the microRNA expression lev-
els obtained from the microRNA microarrays, 10 tumor
and normal paired patient samples were chosen to per-
form real-time quantitative PCR (qPCR) measurements of
miR-375 expression levels (real-time qPCR methods de-
scribed below). Using GraphPad Prism (GraphPad Soft-
ware, La Jolla, CA), Spearman’s correlations were made
between microarray expression signals (log2 trans-
formed) for and the real-time qPCR negative CT values for
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OC P values OP P values LX P values
Down-regulated microRNA
hsa-miR-1 0.712516438 6.15  104 4.52  1017
hsa-miR-100 0.00390454 0.006943608 1.86  107
hsa-miR-10b 0.003819327 0.042310001 6.29  105
hsa-miR-133a 0.999996513 0.003037556 4.52  1017
hsa-miR-134 0.76820037 0.002318016 3.86  105
hsa-miR-135a 3.57  1010 6.10  105 1.80  106
hsa-miR-136 0.001561641 0.857240848 1.88  104
hsa-miR-139 4.77  106 4.86  106 1.08  1015
hsa-miR-140 0.931183432 0.031135886 0.001895523
hsa-miR-150 0.027932224 0.186335748 7.46  104
hsa-miR-154 0.220558911 8.11  105 5.00  107
hsa-miR-195 0.010578937 0.067639679 1.79  106
hsa-miR-204 2.69  1012 2.40  106 4.54  106
hsa-miR-206 0.999996513 0.006593635 2.58  1014
hsa-miR-211 9.16  1012 6.10  105 0.002231787
hsa-miR-214 0.699984085 0.041963914 0.00136318
hsa-miR-218 0.081198903 0.987524453 1.15  105
hsa-miR-299-5p 0.111446474 8.45  104 6.32  105
hsa-miR-30a-3p 2.71  105 0.675332301 1.04  106
hsa-miR-30a-5p 0.013731547 0.788726025 3.59  105
hsa-miR-30e-3p 1.55  104 0.447531324 6.22  104
hsa-miR-328 8.81  108 6.93  106 2.02  109
hsa-miR-329 0.010190082 1.07  105 2.45  105
hsa-miR-338 0.028705319 0.90264997 3.61  104
hsa-miR-368 0.896941625 0.852924356 6.86  105
hsa-miR-370 0.844894578 2.44  105 0.005877478
hsa-miR-375 5.48  1015 2.69  1012 1.75  1017
hsa-miR-378 0.923261456 0.846579697 3.38  106
hsa-miR-379 5.43  105 4.81  108 3.53  109
hsa-miR-382 0.249781331 9.07  105 0.002590983
hsa-miR-411 0.002479555 4.63  105 6.78  107
hsa-miR-432 7.12  105 1.32  107 3.43  1011
hsa-miR-433 0.006593635 6.66  105 4.47  105
hsa-miR-486 0.0309724 0.040751678 0.00464951
hsa-miR-487b 0.025639217 7.35  104 2.57  106
hsa-miR-493-5p 1.18  105 0.194087834 2.38  104
hsa-miR-497 0.069050238 0.676617486 3.30  106
hsa-miR-502 0.314673449 0.058777664 1.39  106
hsa-miR-504 8.18  104 3.46  105 7.47  1011
hsa-miR-519e* 0.160985956 2.35  104 0.016552985
hsa-miR-539 0.193650107 6.62  104 5.04  104
hsa-miR-628 0.002695456 0.259179171 1.20  108
hsa-miR-629 0.965157417 0.073597176 3.66  104
hsa-miR-638 0.023777836 6.50  105 2.29  104
hsa-miR-647 0.878027728 5.13  104 4.29  105
hsa-miR-768-3p 0.040751678 0.15832507 4.91  104
hsa-miR-95 0.005801011 0.823481392 4.92  107
hsa-miR-99a 7.65  105 0.102510318 1.07  1011
HS_108.1 3.28  106 0.30148047 5.80  106
HS_156 0.623543965 5.72  106 2.19  105
HS_158 0.00323098 0.014688193 6.71  108
HS_17 8.34  104 0.001021272 0.008038153
HS_22.1 0.022029435 0.010531887 2.64  104
HS_31.1 1.89  104 0.005472859 0.026877088
HS_41 0.186801144 0.00528058 0.004303429
HS_44.1 0.369968645 5.01  107 3.27  109
Up-regulated microRNA
hsa-miR-105 0.041963914 0.372800395 3.40  109
hsa-miR-106a 9.30  105 0.001072821 7.28  105
hsa-miR-106b 0.00402064 8.18  104 0.003947453
hsa-miR-130b 3.28  106 0.001614984 2.33  107
hsa-miR-142-5p 4.37  108 8.34  104 0.003376405
hsa-miR-144 1.83  105 2.33  109 9.61  106
hsa-miR-147 0.533918715 2.48  106 7.04  106
hsa-miR-154* 3.08  106 0.006188861 0.080474966
hsa-miR-17-3p 1.94  104 0.001042117 5.65  104
hsa-miR-17-5p 1.54  106 6.54  105 0.004171225
hsa-miR-182* 1.18  104 2.68  106 8.73  107(table continues)
indicate
ral cavi
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significant Spearman’s correlation of 0.77 (P  0.0001)
from these 20 tumor and normal samples.
Cell Culture
Two oral cavity SCC cell lines, UMSCC1 and UMSCC47,
were kindly provided by Dr. Thomas Carey from the Uni-
versity of Michigan.39 The 293 cells were purchased from
the American Type Culture Collection (Manassas, VA).
Cell lines weremaintained in a 37°C incubator with 5%CO2.
Cells were cultured in Dulbecco’s modified Eagle’s medium
Table 1. Continued
OC P values
hsa-miR-183 0.001114984
hsa-miR-187 5.37  105
hsa-miR-188 9.97  105
hsa-miR-18a 5.24  106
hsa-miR-18a* 1.90  105
hsa-miR-18b 2.48  106
hsa-miR-193a 0.069050238
hsa-miR-196a 4.84  1012
hsa-miR-196b 1.67  106
hsa-miR-19a 7.79  106
hsa-miR-19b 0.001264768
hsa-miR-213 2.81  105
hsa-miR-219 1.27  106
hsa-miR-301 6.27  109
hsa-miR-31 4.86  107
hsa-miR-32 0.082384129
hsa-miR-33 8.38  108
hsa-miR-33b 1.94  104
hsa-miR-34b 3.17  106
hsa-miR-34c 2.54  107
hsa-miR-421 4.44  104
hsa-miR-431 0.002695456
hsa-miR-450 2.64  106
hsa-miR-452* 5.24  104
hsa-mir-454-3p 9.97  105
hsa-miR-454-5p 0.004231554
hsa-miR-455 7.23  109
hsa-miR-503 6.06  109
hsa-miR-542-3p 5.25  105
hsa-miR-542-5p 7.52  109
hsa-miR-545 0.022591906
hsa-miR-550 0.013123817
hsa-miR-551b 0.193650107
hsa-miR-579 0.009677313
hsa-miR-614 0.073184144
hsa-miR-615 7.12  105
hsa-miR-7 1.33  106
hsa-miR-767-5p 0.008703766
hsa-miR-769-5p 4.59  106
hsa-miR-9* 0.967834217
hsa-miR-96 1.29  104
HS_148 0.591834101
HS_240 0.015247238
HS_301 4.94  104
HS_303_b 3.80  104
HS_307_b 0.499225803
HS_42 1.16  107
HS_58 0.107504336
HS_92.1 1.10  104
Rank consistency score of tumor/normal ratios for miR-375 across thre
on Illumina arrays containing probes representing 736 microRNAs. Bold
HNSCC, head and neck squamous cell carcinoma; LX, larynx; OC, o(DMEM)/High Glucose (Hyclone SH30243) with 100 nmol/Lnonessential amino acids (Gibco 11140, Gibco/Invitrogen)
and 2 mmol/L L-glutamine (Hyclone SH30034). All culture
media were supplemented with 10% fetal bovine serum
(Gibco 10082) and penicillin-streptomycin (100 units/mL
penicillin, 0.1 mg/mL streptomycin).
Generation of Stable HNSCC Oral Cavity
Lentiviral Transductant Cell Lines
The control lentiviral construct (pCDH-CMV-MCS-EF1-
copGFP, System Biosciences, Mountain View, CA) and
the precursor miR-375 lentiviral expression construct
OP P values LX P values
0.032096955 2.65  104
2.86  104 1.13  107
1.85  105 3.32  105
1.66  104 3.83  106
2.37  104 5.43  105
8.97  105 1.32  107
2.08  105 0.112226624
1.89  1010 2.11  1020
4.98  106 4.84  109
4.80  104 6.71  108
0.005227359 0.002581867
0.193650107 0.024150451
3.38  107 8.27  108
2.09  106 2.35  109
0.006115832 0.128374822
8.67  107 1.49  104
2.62  107 5.25  109
5.96  1010 1.27  107
3.06  1012 3.53  109
3.06  1012 3.53  109
0.244763924 1.65  104
0.080465784 3.81  104
0.004658519 1.30  107
0.002211086 0.016350591
2.46  105 3.44  107
0.001834694 8.80  106
5.93  105 2.05  109
3.59  107 4.66  1010
0.249505507 1.54  104
6.66  108 2.56  1013
8.51  105 4.51  104
0.001143935 7.11  104
0.379146072 7.05  105
7.84  107 1.24  107
0.872224892 1.51  106
0.005165919 0.002983365
0.002247075 2.77  108
0.200187863 2.05  108
1.65  104 0.016552985
6.26  1012 8.41  104
3.51  104 7.67  105
4.46  104 0.021464928
0.742369487 0.004131682
0.008106559 0.028625124
0.017829978 3.08  109
1.45  106 1.25  104
2.49  105 3.99  109
0.193650107 2.19  1012
2.03  106 1.03  106
mical sites. Forty-one matched tumor and normal samples were analyzed
s that the gene and data are the subject of the manuscript.
ty; OP, oropharynx.e anato(pMIRH375PA-1, System Biosciences) were cotrans-
922 Harris et al
AJP March 2012, Vol. 180, No. 3fected with packaging plasmids (TAT, REV, GAG/POL)
and pseudotyping plasmid (VSV-G) into 293 cells with
FuGENE transfection reagent (Roche 11815091001,
Roche, Indianapolis, IN). The pseudoviral particle–con-
taining medium was collected 48 hours after transfection
of the 293 cells. The UMSCC1 and UMSCC47 cells were
then transduced with the pseudoviral particle–containing
medium supplemented with polybrene (8 g/mL). Stable
transductants were selected by fluorescence-activated
cell sorting (FACS), matching for similar green fluores-
cent protein (GFP) expression between control and miR-
375 transductants. FACS data were analyzed using
FlowJo (Tree Star, Ashland, OR).
Determination of the in Vitro Growth Rate
A total of 1.25  105 cells were seeded in 2 mL of growth
medium in a 6-well dish. Each cell line was seeded in
triplicate for each time point. Cell counts were taken at
24, 48, and 72 hours. Three independent growth exper-
iments were conducted. Using the exponential growth
equation in GraphPad Prism software, the doubling times
of the cell lines were calculated from each experiment.
The means and standard errors of the doubling times
were determined.
Reverse Transcription and Real-Time qPCR
Total RNA was extracted from the matched transductant
cell lines with TRIzol and 10 ng was used for reverse
transcription using TaqMan MicroRNA Reverse Tran-
scription Kits (Applied Biosystems 4366596) for miR-375
and for RNU 48 (small noncoding RNA control gene)
following their recommended parameter values. Real-
time qPCR reactions were performed in triplicate on an
Applied Biosystems StepOnePlus Real-Time PCR appa-
ratus using TaqMan Universal PCR Master Mix II, No
AmpErase UNG, using their recommended parameters.
For each cell line, a mean CT value was calculated from
the three replicates for miR-375 and RNU 48.40 For each
cell line, the changes in the mean CT values (CT) were
computed by subtracting the mean CT value of RNU 48
(loading control) from the mean CT value of miR-375. To
calculate the change in the CT value in the transductant
cell lines relative to the parental cell lines, CT values were
computed and used to calculate the fold change as 2CT.
In Vitro Invasion Assays
For the in vitro invasion assays, Matrigel Invasion Cham-
bers (24-well inserts, 8-m pores, BD Biosciences
354480) were used. The invasion chambers were rehy-
drated for 2 hours in a 24-well plate with 0.75 mL of plain
DMEM on the outside of the chambers and 0.5 mL of
plain DMEM added to the inside of the chambers. Cells
were detached using Accutase and resuspended in
DMEM  0.7% bovine serum albumin (BSA) at 2  105
cells/mL. The rehydrated invasion chambers were sub-
merged in wells filled with 0.75 mL of either DMEM me-
dium supplemented with 0.7% BSA (DMEM  0.7% BSA
buffer) or 0.1 nmol/L EGF in DMEM  0.7% BSA in a24-well plate. A total of 1  105 cells in 0.5 mL of DMEM 
0.7% BSA were added to the inside of the chamber. The
chambers were covered and incubated for 24 hours at
37°C in a humidified incubator with 5% CO2. After 24
hours, the chambers were fixed in 10% phosphate-buff-
ered formalin for 15 minutes and stained with 0.2% crys-
tal violet for 10 minutes. The cells that had not invaded
were removed by scraping the upper surface of the mem-
brane. A Zeiss STEMI dissecting light microscope (Carl
Zeiss, Oberkochen, Germany) was used to image the
cells that had invaded the lower surface. To quantify the
percent coverage of the membrane with cells, the fraction
of the filter area covered by cells was calculated using
ImageJ (National Institutes of Health, Bethesda, MD).
GraphPad Prism was used to make bar graphs of the
percentage of the membrane covered with cells from
each cell line, and unpaired t-tests were performed to
show statistical differences between the cell lines.
Results
We have conducted an extensive microarray analysis of
tumors and matched normal tissue derived from three
anatomical sites and analyzed the data using a Rank
Consistency Score algorithm developed by Navon and
colleagues.30 The data shown in Table 1 reveal all of the
aberrantly regulated miRNAs as well as the significance
values for each across three anatomical sites of the dis-
ease. We observe miRNAs such as miR-375 whose ex-
pression is affected in all three sites, whereas other
miRNA species exhibit more site specificity in their ex-
pression changes from normal to diseased tissue. One
hundred twenty-three HNSCC patients with first HNSCC
primaries and neighboring normal tissue were next que-
ried for correlations of miR-375 expression levels with
clinicopathological characteristics measured at time of
diagnosis (Table 2). Tumor sites included oral cavity
(35%, n  43), oropharynx (30%, n  37), and larynx
(35%, n  43). Most cases (81%, n  99) presented with
an overall TNM stage of III or IV, and evidence of lymph
node metastases at diagnosis (62%, n  76). The mean
age of patients at diagnosis was 62.2 years (11.9 SD).
We found similar tumor and normal miR-375 expres-
sion levels in this larger cohort as seen in the initial
sample used to select the miRNA candidate (Figure 1).
Significantly lower expression in miR-375 was observed
in tumor compared to adjacent normal tissue samples
from the same patient (median expression  2944.1 in
tumors and 12,086.8 in normal tissue, signed rank test
P  0.00005).
Patients were categorized based on a 25-percentile
cutpoint threshold for a miR-375 T:N expression of 0.116.
Table 2 summarizes the cross-sectional univariate associ-
ations between low versus high miR-375 T:N expression by
demographic and clinicopathological characteristics at di-
agnosis. We detected no significant differences in preva-
lence of low versus high T:N miR-375 expression be-
tween patients grouped based on sociodemographic
and clinicopathological characteristics at diagnosis, al-
though low-stage tumors were somewhat more likely to
ludes: g
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mors. There were also proportionally fewer laryngeal and
oropharyngeal tumors with low miR-375 T:N expression
compared to oral cavity, although the differences were
Table 2. Study Population Characteristics by miR-375 Tumor-to-
Demographic characteristics Total N (%) m
Age at diagnosis (years)
58 45 (36.6)
59–66 38 (30.9)
67 40 (32.5)
Sex
Females 38 (30.9)
Males 85 (69.1)
Race*
White 80 (68.4)
African American 35 (29.9)
Ethnicity*
Non-Hispanic 85 (69.1)
Hispanic/latino 37 (30.1)
Smoking status†
Never smoker 18 (14.6)
Ex-Smoker 57 (46.3)
Current smoker 48 (39.0)
Alcohol drinking†
Never/former 89 (72.4)
Current 34 (27.6)
HPV in tumor*
Negative 74 (60.2)
Positive 31 (25.2)
Clinical characteristics
Anatomical site
Oral cavity 43 (35.0)
Oropharynx 37 (30.1)
Larynx 43 (35.0)
Tumor size
1/2 55 (44.7)
3/4 68 (55.3)
Nodal stage
N0 47 (38.2)
N 76 (61.8)
TNM stage
I//II 24 (19.5)
III/IV 99 (80.5)
ECOG performance*
1 80 (65.0)
2–4 29 (23.6)
Total 123
Low versus high tumor/normal expression ratio groups defined based
*Numbers may not sum to column totals due to missing data or exclu
†Smoking status was defined as never smoked, ex-smoker (at time of
drank alcohol regularly or current drinker at time of diagnosis.
‡Oral cavity includes: alveolar ridge, anterior tongue, floor of mouth, h
soft palate, oropharyngeal wall, uvula, and orophrarynx-NOS. Larynx inc
ECOG, Eastern Cooperative Oncology Group.not significant. This is in accord with Avissar et al24 who
noted higher miR-375 expression in pharyngeal and la-
ryngeal tumors compared with those in the oral cavity.
We tested for a linear association with decreased miR-
Expression Level
high (%) miR-375 low (%) 2 test P value
80.0) 9 (20.0)
71.0) 11 (29.0)
80.0) 8 (20.0) 0.550
84.2) 6 (15.8)
74.1) 22 (25.9) 0.217
75.0) 20 (25.0)
88.6) 4 (11.4) 0.099
80.0) 17 (20.0)
70.3) 11 (29.7) 0.240
72.2) 5 (27.8)
73.7) 15 (26.3)
83.3) 8 (16.7) 0.431
78.6) 19 (21.4)
73.5) 9 (26.5) 0.545
75.7) 18 (24.3)
74.2) 8 (25.8) 0.872
69.8) 13 (30.2)
78.4) 8 (21.6)
83.7) 7 (16.3) 0.298
72.7) 15 (27.3)
80.9) 13 (19.1) 0.284
76.6) 11 (23.4)
77.6) 17 (22.4) 0.894
62.5) 9 (37.5)
80.8) 19 (19.2) 0.055
77.5) 18 (22.5)
82.8) 5 (17.2) 0.552
5 28
5-percentile cutpoint.
“unknown/other” categories.
is), and current smoker. Drinking status was defined as never or formerly
late, and retromolar trigone. Oropharynx includes base of tongue, tonsil,
lottis and supraglottis, and false vocal cord.
Figure 1. Box-plot distributions of tumor and
adjacent normal tissue expression levels. Left
panel: distributions of primary tumor and adja-
cent normal tissue miR-375 expression levels as
determined by microarray analysis. Right panel:
distribution of tumor-to-normal miR-375 expres-
sion ratios in HNSCC patients.Normal
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AJP March 2012, Vol. 180, No. 3375 T:N expression assuming multiple percentile catego-
ries but detected no dose-response relationship. The 25-
percentile cutpoint was therefore chosen to show a
threshold effect with prognosis.
Low miR-375 Expression in HNSCC Tumor
versus Adjacent Normal Tissue Is Correlated
with Poor Prognosis
To evaluate survival and disease progression in patients
by miR-375 T:N expression, we plotted Kaplan-Meier
curves to show survival functions by miR-375 expression
status (Figure 2), and constructed multivariable Cox pro-
portional hazards regression models to estimate the HR
of dying and developing a locoregional recurrence or
Figure 2. Patients with low miR-375 tumor-to-normal (T:N) expression ra-
tios have worse prognosis. Kaplan-Meier plots for cancer survival (A), lo-
coregional recurrence (B), and distant metastasis (C) by miR-375 tumor-to-
normal expression ratio. Kaplan-Meier function curves are plotted for low
(solid lines) versus high (dashed lines) tumor-to-normal (T:N) expression
ratio groups, defined based on a 25-percentile cutpoint. Censored subjects
are indicated by vertical hash marks.distant metastasis, adjusting for prognostic indicatorsand confounders. The strongest demographic and clini-
cal prognostic factors for survival across all tumor sites
included: age, tumor site, nodal metastases at diagnosis,
and treatment regimen. Adjusting for these indicators
and the additional negative confounder, sex, patients
with lower miR-375 T:N expression were more likely to die
of disease (HR: 12.8, 95% CI: 3.4 to 48.6) than those with
higher miR-375 T:N (Table 3). Weaker, but nonetheless
significant, risk associations were also observed with in-
cidence of locoregional recurrence (HR: 3.9, 95% CI: 1.1
to 13.4) and distant metastasis (HR: 8.7, 95% CI: 2.4 to
31.0). Further adjustment for HPV, race, ethnicity, Eastern
Cooperative Oncology Group performance status, smok-
ing, or alcohol consumption did not substantively change
the HRs for miR-375. Adjustment for overall TNM staging
introduced a collinear relationship with nodal metastases,
which showed a stronger association with clinical out-
come. Further adjustment of percentage of cancer cells
in the tumor specimen (available on 120 cases) did not
substantively affect the adjusted HR for miR-375 T:N ex-
pression. Percent tumor in the specimen was also not
related with clinical outcome. We detected no significant
violations of proportional hazards assumptions for the
adjusted multivariable models.
We also tested for differential effects by anatomic tu-
mor site, nodal stage at diagnosis, and primary treatment
regimen. No statistical differences in cancer survival, risk
of locoregional recurrence, and distant metastasis with
lower miR-375 T:N expression were detected by ana-
tomic site (Table 3), nor by nodal stage at diagnosis or
primary treatment regimen, including surgery and/or
chemoradiation therapy (not shown). When restricted on
tumor site, we see inverse associations with miR-375 T:N
expression across all primary tumor sites within the head
and neck, albeit with limited power to detect significant
associations or fully adjust for confounding for some of
the clinical outcomes. However, significant associations
were observed with cancer death and occurrence of
distant metastases for oral cavity and larynx tumors.
MiRNA expression status was assessed as a ratio of
miR-375 expression in the tumor relative to adjacent nor-
mal tissue collected from the same patient to provide a
normalized ratio across the study population. However,
we also assessed the clinical association with absolute
expression levels in the tumor only. No significant asso-
ciation was observed with decreased expression of miR-
375 in the tumor with head and neck cancer survival (HR:
1.4, 95% CI: 0.3 to 6.0), locoregional recurrence (HR: 1.4,
95% CI: 0.2 to 8.4), or distant metastasis (HR: 1.4, 95%
CI: 0.3 to 5.8) adjusting for tumor site, age, sex, nodal
status, primary treatment, and percent tumor.
miR-375 Overexpression in UMSCC1 and
UMSCC47 Oral Cavity SCC Cell Lines
Reduces Invasion
The highly significant association of lower miR-375 ex-
pression in patients with poor prognosis and distant me-
tastasis led us to test for phenotypic changes in cells
caused by ectopic overexpression in cultured HNSCC
, where
e detect
miR-375 and HNSCC Malignancy 925
AJP March 2012, Vol. 180, No. 3cell lines. UMSCC1 and UMSCC47 HNSCC cell lines are
derived from oral cavity tumors39 and exhibit low levels of
miR-375, consistent with the primary HNSCC patient tu-
mor data described above. To characterize the impact of
miR-375 on HNSCC phenotypes, stable lentiviral trans-
ductants were generated from these two cell lines using
the System Biosciences pCDH lentiviral vectors. We used
FACS for the coexpressed GFP marker to identify stable
transductants and to collect pools of cells matched for
viral levels (Figure 3, A and B). We used real-time qPCR
to determine miR-375 expression levels in the UMSCC1
and UMSCC47 precursor miR-375 transductant cell lines
relative to their respective control cell lines. The precur-
sor miR-375 transductant cell lines showed 13,500 fold
(UMSCC47) or 11,500 fold (UMSCC1) increases in
miR-375 expression (Figure 3C). To test whether expres-
sion of miR-375 had any effect on the growth rate of the
transductant cell lines, the doubling times of the trans-
ductant lines were measured. There were no significant
changes in growth rate for either of the precursor miR-
375–expressing transductant lines compared to their
corresponding empty vector control lines. The mean dou-
bling times of the UMSCC1 control and Pre-375 trans-
ductant cell lines were 25.23 and 26.71 hours, respec-
tively (P  0.62); the mean doubling times of the
UMSCC47 control and Pre-375 transductant cell lines
were 22.72 and 23.10 hours, respectively (P  0.88).
We then explored whether overexpression of miR-375
alters cell invasion using Matrigel Invasion Chambers.
Invasion in the presence of buffer or epidermal growth
factor (EGF) of the UMSCC1 and UMSCC47 transductant
cell lines was assessed after 24 hours. The two cell lines
showed very similar effects of miR-375 expression on
invasion (Figure 4, A and B). Invasion in response to
buffer (absence of any gradient) was reduced by at least
70%. In the empty vector control lines, EGF induced a
roughly 3-fold increase in the number of cells invading
across the membrane. The lines expressing miR-375
showed a 40% reduction in invasion in response to EGF.
All changes induced by expression of miR-375 were sta-
Table 3. Multivariable HR for Overall, Disease-Specific, and Prog
Expression
miR-375 T:N expression ratio
(low versus high)
Head and neck
cancer death
All sites combined
Adjusted* model 1 16.5 (4.4–61.6)
Adjusted† model 2 12.8 (3.4–48.6)
Adjusted‡ model 3 15.7 (4.0–60.0)
By tumor site§
Oral cavity 12.4 (1.4–104.2)
Oropharynx NS¶
Larynx 14.5 (1.9–112.7)
Low (exposed group) versus high (reference group) tumor-to-normal
*Hazard risk ratios (HR) and 95% confidence intervals (CI) estimated
treatment.
†HR additionally adjusted for sex and variables in model 1.
‡HR additionally adjusted for percent tumor in specimen and variable
§Site-restricted HR adjusted for age, sex, nodal status, and treatment
¶Results for oropharyngeal SCC are not shown (NS), as all events wertistically significant.Discussion
One of the great promises of molecular classification of
tumor samples using genomic platforms will be to guide
the best treatment options for individual patients based
on their genetics. To achieve this goal, we need clinically
relevant biomarkers that offer reliable assessment of risks
-Free Survival for Low versus High miR-375 Tumor-to-Normal
HR (95% CI)
Distant
metastasis
Locoregional
recurrence Overall death
.3 (3.2–39.2) 4.7 (1.4–15.8) 1.6 (0.8–3.2)
.7 (2.4–31.0) 3.9 (1.1–13.4) 1.6 (0.8–3.1)
.8 (2.3–27.0) 3.7 (1.1–12.8) 1.6 (0.8–3.2)
.4 (1.8–171.4) 1.9 (0.3–14.0) 1.1 (0.4–3.0)
NS¶ 3.0 (0.1–60.0) 5.6 (0.7–44.2)
.9 (1.4–44.8) 3.7 (0.6–23.5) 1.9 (0.6–6.1)
ion ratio groups were defined based on a 25-percentile cutpoint.
ltivariable Cox regression adjusted for tumor site, age, nodal status and
del 2.
numbers permitted.
ed in the high tumor-to-normal miR-375 expression (ie, reference) group.
Figure 3. FACS analysis of GFP expression and fold change in miR-375
expression levels in UMSCC1 and UMSCC47 transductant cell lines. Trans-
ductants were sorted for similar GFP expression for precursor miR-375
(PRE375) and empty vector control (control) transductants of UMSCC1 (A)
and UMSCC47 (B). Fold change in the miR-375 expression levels in theression
11
8
7
17
7
express
by mu
s in moUMSCC1 and UMSCC47 pre-375 transductant cell lines relative to the control
transductant lines as measured by real-time quantitative PCR (C).
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is particularly true for HNSCC, where survival rates have
been relatively unchanged for decades and where can-
didate biomarkers such as p53, EGFR, Bcl-2, MMPs,
cyclins, and others have not proven to be clinically rele-
vant.17–19 MicroRNAs have been studied as candidate
biomarkers of clinically relevant phenotypes in several
cancer models,9–16 and we have previously established
that miR-205 and let-7d may be of use to predict outcome
and locoregional recurrence.11 In that study, we used
spotted microarrays probing 236 miRNAs and a small
cohort of patient samples to identify a few misregulated
candidate miRNAs to examine in a larger patient popu-
lation using real-time qPCR. Here, we used the Illumina
miRNA microarray platform31 to probe 736 miRNAs from
a larger patient population from which we were able to
identify miR-375 as the single most differentially ex-
pressed miRNA between tumor and normal tissue de-
rived from oral cavity, oropharynx, and larynx SCC pa-
tients.
This result using a different HNSCC patient population
is in support of previous reports indicating that lower
levels of miR-375 are extremely common in primary tu-
mors.14,26,29 We sought to extend the results of other
studies showing the significance of lower miR-375 ex-
pression levels in primary tumors by evaluating the prog-
nostic role of miR-375 expression in HNSCC within our
patient population, including oral cavity, pharyngeal and
laryngeal samples. We assessed survival and disease
progression in HNSCC patients by miR-375 expression
levels. A key finding from this study is the significant
association between low miR-375 tumor versus normal
tissue expression and cancer progression and metastatic
spread, both locally and outside the head and neck.
There were both strengths and limitations to our ap-
proach. Among the former, we had available for testing
fresh-frozen tumor and adjacent normal tissue samples
from newly diagnosed HNSCC cases collected for re-
Figure 4. Invasion is reduced in miR-375 transductant cell lines. Basal
(buffer without EGF) and EGF-stimulated (0.1 nmol/L EGF) in vitro invasion
were evaluated for transductant cell lines carrying empty vector control
(control) or miR-375 vector (PRE375) of UMSCC1 (A) and UMSCC47 (B). Data
are represented as means and SEM of 18 (UMSCC47) or 11 (UMSCC1)
measurements. ***P  0.0001.search purposes, reducing the potential for RNA degra-dation. Furthermore, we were able to assess prospective
associations with disease-specific events including tu-
mor recurrence and distant metastasis, adjusting for clin-
icopathological factors using multivariable Cox regres-
sion. We also see inverse associations with miR-375 T:N
expression across tumor sites within the head and neck,
albeit with limited power for some of the clinical out-
comes, suggesting this may be a prognostic biomarker
for HNSCC. Nonetheless, given the relatively small sam-
ple sizes and inherent heterogeneity in the progression of
HNSCC, we cannot rule out possible residual confound-
ing or interaction by treatment or anatomical site. We
were able to confirm the results of others24,29 that oral
cavity SCC had less miR-375 than pharyngeal and laryn-
geal SCC. Nevertheless, using matched normal tissue
from the same patients, we also show that miR-375 ex-
pression was significantly reduced in pharyngeal and
laryngeal SCC tumors. In addition, we were not suffi-
ciently powered to detect differences in miR-375–asso-
ciated survival or disease progression among low-stage
tumors.
MiRNA-375 was first identified as a critical regulator of
glucose homeostasis in pancreatic islets, where it regu-
lates insulin secretion and cell mass.41 however, it has
also been implicated in gastric cancer,15,42,43 hepatocel-
lular carcinoma,44 breast cancer,45 and head and neck
cancer.24,26 It is frequently down-regulated in gastric
cancer, where it has been shown in cell culture to target
PDK1, 14-3-3,42 and JAK2.43 These targets, implicated
using transient transfection of miR-375 precursor RNA in
gastric cancer cell lines to re-express the miRNA, re-
vealed roles in cell proliferation, apoptosis, and cell sur-
vival.42,43 Similarly, miR-375 has been reported to target
the Hippo-signaling pathway through Yes-associated
protein (YAP) in hepatocellular carcinoma, causing inhi-
bition of cell proliferation and invasion.44 We chose to
make stable SCC cell lines from the oral cavity that differ
only in that one line overexpresses miR-375, because we
believe that this steady-state condition would better
mimic actual tumor cell conditions needed for under-
standing phenotypic changes caused by the miRNA. We
generated pools of stable transductants, using GFP ex-
pression to identify transductants and match for viral
load. During the generation of the transductants, we did
not observe any obvious differences in growth rate of
miR-375 transductants compared to empty vector trans-
ductants. Consistent with this initial observation, more
detailed analysis of the stable transductants also showed
little difference in proliferation rate between empty vector
control and miR-375 overexpressing lines. The literature
is mixed regarding the effect of miR-375 on cell prolifer-
ation. Transient transfection experiments have indicated
that miR-375 can reduce proliferation of hepatocellular
carcinoma and gastric carcinoma cells, but stimulates
proliferation of estrogen receptor–positive breast cancer
cells. For other HNSCC sites, overexpression of miR-375
using transient transfection of precursor miR-375 RNA in
FaDu cells, a hypopharyngeal SCC, reduced prolifera-
tion, but not in two other laryngeal SCC cell lines
(UTSCC-8 and UTSCC-42a).29 Our data are the first re-
sults presented for HNSCC cell lines that are stably ex-
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with the results seen for UTSCC-8 and UTSCC-42a. Thus,
it seems unlikely that the reduced patient survival that we
observe is due to effects on proliferation.
Instead, our invasion analysis suggests that miR-375
expression could contribute to patient survival by reduc-
ing invasion. There was a significant decrease in both
basal levels of invasion and EGF-induced invasion with
increased expression of miR-375 in the oral cavity cell
lines. The observed correlation between tumors with low
levels of miR-375 and worse prognosis could reflect in-
creased invasive capabilities of tumors with low miR-375.
There is one previous report of miR-375 expression re-
sulting in reduced invasion for hepatocellular carcinoma,
but because in those cells, miR-375 also significantly
affected cell proliferation, it is possible that the altered
rate of wound healing that was observed was due to the
reduced cell proliferation rate. Our studies demonstrate
that miR-375 expression can reduce invasion in the ab-
sence of any effects on cell proliferation, suggesting that
miR-375 may directly affection invasion pathways. A
number of validated miR-375 targets can contribute to
tumor cell invasion, including YAP1, JAK2, and PDK1.
Future studies will involve testing whether the mechanism
by which miR-375 suppresses invasion is through reduc-
tion in the expression of these or other potential miR-375
targets.
The literature suggests that the significance of the ex-
pression level of miR-375 could be cell-type dependent.
Both adenocarcinomas and SCC of the esophagus with
significantly higher levels of miR-21 and lower levels of
miR-375 are strongly associated with worse prognosis.46
HNSCC are, like most solid tumors, frequently associated
with high miR-21 levels,2,3 raising the possibility of similar
combinatorial risk factors. We observed no significant
correlation of high miR-21 levels with prognosis in a 104-
patient cohort11; however, in another study using a dif-
ferent cohort of 169 patients, high miR-21 expression was
associated with significantly decreased 5-year survival in
patients (HR: 1.68; 95% CI: 1.04 to 2.77) in a model that
controlled for patient age, sex, and tumor stage.24 In
HNSCC, the expression ratio of miR-221/miR-375 has
been shown to distinguish diseased HNSCC tumor from
nondiseased epithelia.14 For gastric cancer, one study
found higher expression of miR-375 in combination with
low levels of miR-142-5p to predict risk of recurrence,15
whereas two other reports showed significantly lower
miR-375 expression in tumors compared with normal tis-
sue.42,43 These observations raise the possibility that cel-
lular context, as well as the specific phenotypes exam-
ined, is likely to be influenced by different sets of target
mRNAs whose expression may be cell type specific and
therefore disease specific yet targeted by the same sin-
gle miRNA. These studies suggest that the use of com-
binatorial measurements of miRNAs as prognostic tools
is likely to be tumor specific.
In conclusion, we have demonstrated that miR-375
expression levels can predict risk of poor outcome and
distant metastasis in HNSCC regardless of the tumor site.
Our data suggest that for HNSCC, this correlation could
be due to effects of miR-375 on tumor cell invasion. Theidentification of patients with a poor prognosis, especially
in the case of early-stage disease, could lead to addi-
tional therapeutic interventions, such as suppressing tu-
mor cell invasiveness, to achieve better outcomes.
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